Pharmaceutical and Analytical Development Department, Novartis Pharmaceuticals Corp., East Hanover, NJ 07936, United States.
Int J Pharm. 2009 Oct 20;381(1):56-61. doi: 10.1016/j.ijpharm.2009.05.043. Epub 2009 May 30.
The preparation of tablets by the melt granulation process was investigated to enhance chemical stability of a highly water-soluble drug substance, dipeptidylpeptidase IV (DPP-IV) inhibitor (Compound I), that is susceptible to degradation in presence of moisture. Melt granulation with a lipophilic binder (hydrogenated castor oil; Cutina HR) improved the stability of the drug, while still maintaining immediate-release characteristics of the drug product. The drug to binder ratio was shown to impact the degradation behavior of the drug product. With higher binder levels, the sensitivity of the drug to degradation under humidity conditions decreased. It is postulated that the lipophilic binder coated drug particles at the surface protecting them from the influence of moisture. The granules had good flow properties and good compressibility and tablets prepared from them exhibited low weight variation and low friability.
采用热熔制粒法制备片剂,以提高高度水溶性药物二肽基肽酶-4(DPP-4)抑制剂(化合物 I)的化学稳定性。该药物易在存在水分的情况下发生降解。采用亲脂性赋形剂(氢化蓖麻油;Cutina HR)的热熔制粒可改善药物的稳定性,同时仍保持药物产品的速释特征。药物与赋形剂的比例会影响药物产品的降解行为。随着赋形剂水平的提高,药物在湿度条件下降解的敏感性降低。据推测,亲脂性赋形剂在药物颗粒表面形成涂层,保护其免受水分的影响。制得的颗粒具有良好的流动性和可压缩性,由其制备的片剂重量差异小、脆碎度低。